Kezar Life Sciences (KZR) Equity Average (2021 - 2025)
Kezar Life Sciences (KZR) has disclosed Equity Average for 5 consecutive years, with $76.5 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 39.02% to $76.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.5 million through Dec 2025, down 39.02% year-over-year, with the annual reading at $93.5 million for FY2025, 38.59% down from the prior year.
- Equity Average hit $76.5 million in Q4 2025 for Kezar Life Sciences, down from $87.4 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $290.3 million in Q3 2022 to a low of $76.5 million in Q4 2025.
- Historically, Equity Average has averaged $177.4 million across 5 years, with a median of $159.9 million in 2024.
- Biggest five-year swings in Equity Average: surged 132.81% in 2022 and later tumbled 39.07% in 2025.
- Year by year, Equity Average stood at $158.2 million in 2021, then skyrocketed by 74.82% to $276.5 million in 2022, then decreased by 27.03% to $201.8 million in 2023, then plummeted by 37.81% to $125.5 million in 2024, then plummeted by 39.02% to $76.5 million in 2025.
- Business Quant data shows Equity Average for KZR at $76.5 million in Q4 2025, $87.4 million in Q3 2025, and $97.4 million in Q2 2025.